• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Haematological improvement as a beneficial effect during deferasirox treatment in transfusion-dependent patients with myelodysplastic syndrome.对于依赖输血的骨髓增生异常综合征患者，去铁胺治疗期间血液学改善是一种有益效果。
Blood Transfus. 2014 Jan;12 Suppl 1(Suppl 1):s162-3. doi: 10.2450/2013.0005-13. Epub 2013 Apr 15.
2
An update on iron chelation therapy.铁螯合疗法的最新进展。
Blood Transfus. 2012 Oct;10(4):411-22. doi: 10.2450/2012.0008-12. Epub 2012 Jun 27.
3
The treatment of secondary hemochromatosis.继发性血色素沉着症的治疗。
Dtsch Arztebl Int. 2009 Jul;106(30):499-504, I. doi: 10.3238/arztebl.2009.0499. Epub 2009 Jul 24.
4
Daily alternating deferasirox and deferiprone therapy successfully controls iron accumulation in untreatable transfusion-dependent thalassemia patients.每日交替使用地拉罗司和去铁酮疗法成功控制了无法治疗的输血依赖型地中海贫血患者的铁蓄积。
Am J Hematol. 2018 Oct;93(10):E338-E340. doi: 10.1002/ajh.25222. Epub 2018 Aug 14.
5
Current recommendations for chelation for transfusion-dependent thalassemia.目前对依赖输血的地中海贫血症进行螯合治疗的建议。
Ann N Y Acad Sci. 2016 Mar;1368(1):107-14. doi: 10.1111/nyas.13088.
6
Optimising management of deferasirox therapy for patients with transfusion-dependent thalassaemia and lower-risk myelodysplastic syndromes.优化依赖输血的地中海贫血和低危骨髓增生异常综合征患者的地拉罗司治疗管理。
Eur J Haematol. 2018 Sep;101(3):272-282. doi: 10.1111/ejh.13111. Epub 2018 Jul 27.
7
Cardiac Hemochromatosis Treated With Prolonged Extracorporeal Membrane Oxygenation Support and Chelation Therapy.
Artif Organs. 2018 May;42(5):575-576. doi: 10.1111/aor.13076.
8
Magnetic resonance imaging during management of patients with transfusion-dependent thalassemia: a single-center experience.输血依赖型地中海贫血患者管理期间的磁共振成像：单中心经验。
Radiol Med. 2018 Aug;123(8):572-576. doi: 10.1007/s11547-018-0889-0. Epub 2018 Apr 16.
9
A holistic approach to iron chelation therapy in transfusion-dependent thalassemia patients with serum ferritin below 500 μg/L.对血清铁蛋白低于500μg/L的输血依赖型地中海贫血患者进行铁螯合治疗的整体方法。
Am J Hematol. 2020 Sep;95(9):E230-E232. doi: 10.1002/ajh.25860. Epub 2020 Jun 15.
10
Iron chelation therapy in hereditary hemochromatosis and thalassemia intermedia: regulatory and non regulatory mechanisms of increased iron absorption.遗传性血色素沉着症和中间型地中海贫血中的铁螯合疗法：铁吸收增加的调节和非调节机制
Hemoglobin. 2010 Jun;34(3):251-64. doi: 10.3109/03630269.2010.486335.

引用本文的文献

1
Low-risk MDS-A spotlight on precision medicine for mutated patients.低风险骨髓增生异常综合征——聚焦于针对突变患者的精准医学
Hemasphere. 2025 Mar 21;9(3):e70103. doi: 10.1002/hem3.70103. eCollection 2025 Mar.
2
Lower-risk myelodysplastic syndromes: Current treatment options for anemia.低危骨髓增生异常综合征：贫血的当前治疗选择
EJHaem. 2022 Aug 12;3(4):1091-1099. doi: 10.1002/jha2.523. eCollection 2022 Nov.
3
Reactive oxygen species levels control NF-κB activation by low dose deferasirox in erythroid progenitors of low risk myelodysplastic syndromes.活性氧水平通过低剂量地拉罗司控制低危骨髓增生异常综合征红系祖细胞中NF-κB的激活。
Oncotarget. 2017 Nov 6;8(62):105510-105524. doi: 10.18632/oncotarget.22299. eCollection 2017 Dec 1.
4
Long-term hematological response in a patient with 5q- syndrome after suspension of lenalidomide therapy and further improvement with deferasirox therapy.来那度胺治疗中断后5q-综合征患者的长期血液学反应及地拉罗司治疗后的进一步改善
Blood Res. 2014 Jun;49(2):130-7. doi: 10.5045/br.2014.49.2.130. Epub 2014 Jun 25.
5
Iron chelation therapy with deferasirox in the management of iron overload in primary myelofibrosis.用地拉罗司进行铁螯合疗法治疗原发性骨髓纤维化中的铁过载
Mediterr J Hematol Infect Dis. 2014 Jun 1;6(1):e2014042. doi: 10.4084/MJHID.2014.042. eCollection 2014.

本文引用的文献

1
An update on iron chelation therapy.铁螯合疗法的最新进展。
Blood Transfus. 2012 Oct;10(4):411-22. doi: 10.2450/2012.0008-12. Epub 2012 Jun 27.
2
Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population.地拉罗司治疗骨髓增生异常综合征：单中心患者人群中的“真实世界”疗效和安全性。
Ann Hematol. 2012 Sep;91(9):1345-9. doi: 10.1007/s00277-012-1481-7. Epub 2012 May 9.
3
Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes.去铁斯若治疗依赖输血的骨髓增生异常综合征患者的血液学反应
Haematologica. 2012 Sep;97(9):1364-71. doi: 10.3324/haematol.2011.048546. Epub 2012 Mar 14.
4
Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: a brief review.地拉罗司治疗骨髓增生异常综合征患者的造血作用：简要综述。
Leuk Res. 2011 May;35(5):566-70. doi: 10.1016/j.leukres.2010.11.027. Epub 2010 Dec 23.
5
Deferasirox treatment interruption in a transfusion-requiring myelodysplastic patient led to loss of erythroid response.一名需要输血的骨髓增生异常综合征患者中断地拉罗司治疗导致红系反应丧失。
Acta Haematol. 2010;124(1):46-8. doi: 10.1159/000314961. Epub 2010 Jul 9.

Haematological improvement as a beneficial effect during deferasirox treatment in transfusion-dependent patients with myelodysplastic syndrome.

作者信息

Molica Matteo, Salaroli Adriano, Alimena Giuliana, Breccia Massimo

机构信息

Department of Cellular Biotechnologies and Haematology, Sapienza University, Rome, Italy.

出版信息

Blood Transfus. 2014 Jan;12 Suppl 1(Suppl 1):s162-3. doi: 10.2450/2013.0005-13. Epub 2013 Apr 15.

DOI:10.2450/2013.0005-13
PMID:23736908
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3934268/
Abstract
摘要